183 related articles for article (PubMed ID: 18024704)
21. Autotaxin protects MCF-7 breast cancer and MDA-MB-435 melanoma cells against Taxol-induced apoptosis.
Samadi N; Gaetano C; Goping IS; Brindley DN
Oncogene; 2009 Feb; 28(7):1028-39. PubMed ID: 19079345
[TBL] [Abstract][Full Text] [Related]
22. Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts.
David M; Wannecq E; Descotes F; Jansen S; Deux B; Ribeiro J; Serre CM; Grès S; Bendriss-Vermare N; Bollen M; Saez S; Aoki J; Saulnier-Blache JS; Clézardin P; Peyruchaud O
PLoS One; 2010 Mar; 5(3):e9741. PubMed ID: 20305819
[TBL] [Abstract][Full Text] [Related]
23. Autotaxin is induced by TSA through HDAC3 and HDAC7 inhibition and antagonizes the TSA-induced cell apoptosis.
Li S; Wang B; Xu Y; Zhang J
Mol Cancer; 2011 Feb; 10():18. PubMed ID: 21314984
[TBL] [Abstract][Full Text] [Related]
24. Requirement of Osteopontin in the migration and protection against Taxol-induced apoptosis via the ATX-LPA axis in SGC7901 cells.
Zhang R; Wang J; Ma S; Huang Z; Zhang G
BMC Cell Biol; 2011 Mar; 12():11. PubMed ID: 21406114
[TBL] [Abstract][Full Text] [Related]
25. Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis.
Baker DL; Fujiwara Y; Pigg KR; Tsukahara R; Kobayashi S; Murofushi H; Uchiyama A; Murakami-Murofushi K; Koh E; Bandle RW; Byun HS; Bittman R; Fan D; Murph M; Mills GB; Tigyi G
J Biol Chem; 2006 Aug; 281(32):22786-93. PubMed ID: 16782709
[TBL] [Abstract][Full Text] [Related]
26. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production.
Umezu-Goto M; Kishi Y; Taira A; Hama K; Dohmae N; Takio K; Yamori T; Mills GB; Inoue K; Aoki J; Arai H
J Cell Biol; 2002 Jul; 158(2):227-33. PubMed ID: 12119361
[TBL] [Abstract][Full Text] [Related]
27. Autotaxin (lysoPLD/NPP2) protects fibroblasts from apoptosis through its enzymatic product, lysophosphatidic acid, utilizing albumin-bound substrate.
Song J; Clair T; Noh JH; Eun JW; Ryu SY; Lee SN; Ahn YM; Kim SY; Lee SH; Park WS; Yoo NJ; Lee JY; Nam SW
Biochem Biophys Res Commun; 2005 Nov; 337(3):967-75. PubMed ID: 16219296
[TBL] [Abstract][Full Text] [Related]
28. Autotaxin/lysopholipase D and lysophosphatidic acid regulate murine hemostasis and thrombosis.
Pamuklar Z; Federico L; Liu S; Umezu-Goto M; Dong A; Panchatcharam M; Fulkerson Z; Berdyshev E; Natarajan V; Fang X; van Meeteren LA; Moolenaar WH; Mills GB; Morris AJ; Smyth SS
J Biol Chem; 2009 Mar; 284(11):7385-94. PubMed ID: 19139100
[TBL] [Abstract][Full Text] [Related]
29. Regulation of lysophosphatidate signaling by autotaxin and lipid phosphate phosphatases with respect to tumor progression, angiogenesis, metastasis and chemo-resistance.
Samadi N; Bekele R; Capatos D; Venkatraman G; Sariahmetoglu M; Brindley DN
Biochimie; 2011 Jan; 93(1):61-70. PubMed ID: 20709140
[TBL] [Abstract][Full Text] [Related]
30. Autotaxin: a protein with two faces.
Tania M; Khan MA; Zhang H; Li J; Song Y
Biochem Biophys Res Commun; 2010 Oct; 401(4):493-7. PubMed ID: 20888793
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate.
van Meeteren LA; Ruurs P; Christodoulou E; Goding JW; Takakusa H; Kikuchi K; Perrakis A; Nagano T; Moolenaar WH
J Biol Chem; 2005 Jun; 280(22):21155-61. PubMed ID: 15769751
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic potential of autotaxin/lysophospholipase d inhibitors.
Federico L; Pamuklar Z; Smyth SS; Morris AJ
Curr Drug Targets; 2008 Aug; 9(8):698-708. PubMed ID: 18691016
[TBL] [Abstract][Full Text] [Related]
33. High-fat diet, obesity and prostate disease: the ATX-LPA axis?
Kulkarni P; Getzenberg RH
Nat Clin Pract Urol; 2009 Mar; 6(3):128-31. PubMed ID: 19204739
[No Abstract] [Full Text] [Related]
34. Regulation and biological activities of the autotaxin-LPA axis.
van Meeteren LA; Moolenaar WH
Prog Lipid Res; 2007 Mar; 46(2):145-60. PubMed ID: 17459484
[TBL] [Abstract][Full Text] [Related]
35. Lysophospholipids in the limelight: autotaxin takes center stage.
Moolenaar WH
J Cell Biol; 2002 Jul; 158(2):197-9. PubMed ID: 12135981
[TBL] [Abstract][Full Text] [Related]
36. Autotaxin, an ectoenzyme that produces lysophosphatidic acid, promotes the entry of lymphocytes into secondary lymphoid organs.
Kanda H; Newton R; Klein R; Morita Y; Gunn MD; Rosen SD
Nat Immunol; 2008 Apr; 9(4):415-23. PubMed ID: 18327261
[TBL] [Abstract][Full Text] [Related]
37. New insights into the autotaxin/LPA axis in cancer development and metastasis.
Leblanc R; Peyruchaud O
Exp Cell Res; 2015 May; 333(2):183-189. PubMed ID: 25460336
[TBL] [Abstract][Full Text] [Related]
38. Exogenous phospholipase D generates lysophosphatidic acid and activates Ras, Rho and Ca2+ signaling pathways.
van Dijk MC; Postma F; Hilkmann H; Jalink K; van Blitterswijk WJ; Moolenaar WH
Curr Biol; 1998 Mar; 8(7):386-92. PubMed ID: 9545198
[TBL] [Abstract][Full Text] [Related]
39. Fluorogenic phospholipid substrate to detect lysophospholipase D/autotaxin activity.
Ferguson CG; Bigman CS; Richardson RD; van Meeteren LA; Moolenaar WH; Prestwich GD
Org Lett; 2006 May; 8(10):2023-6. PubMed ID: 16671772
[TBL] [Abstract][Full Text] [Related]
40. Lysophosphatidic acid inhibits adipocyte differentiation via lysophosphatidic acid 1 receptor-dependent down-regulation of peroxisome proliferator-activated receptor gamma2.
Simon MF; Daviaud D; Pradère JP; Grès S; Guigné C; Wabitsch M; Chun J; Valet P; Saulnier-Blache JS
J Biol Chem; 2005 Apr; 280(15):14656-62. PubMed ID: 15710620
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
